Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

May 30, 2024

https://www.globenewswire.com/news-release/2024/05/30/2890593/0/en/Gain-Therapeutics-Announces-Acceptance-of-Late-Breaking-Abstract-for-Poster-Presentation-at-Federation-of-European-Neuroscience-Societies-FENS-Forum-2024.html

BETHESDA, Md., May 30, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq:GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late-breaking abstract with new data on GT-02287 has been accepted for presentation at FENS Forum 2024 being held June 25-29, 2024 in Vienna, Austria. The poster highlights improvements in cognitive performance in a preclinical model of GBA1 Parkinson’s disease. The FENS Forum is Europe’s largest neuroscience congress, covering all areas of neuroscience from basic to translational research.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.